DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was ...

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on ...

25 analysts are following DexCom and have set target prices ranging from $82.0 to $110.0 per share. On average, they have ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Shares of DexCom Inc. DXCM shed 1.11% to $84.11 Tuesday, on what proved to be an all-around mixed trading session for the ...

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO.

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...